17-α羟孕酮己酸酯起始孕周与复发性早产的关系
该回顾性队列研究纳入132例既往16-28周自发性早产、本次妊娠接受17-α羟孕酮己酸酯的单胎孕妇,按起始孕周四分位分组。早期起始组复发性早产<37周发生率趋向低于晚期起始组(41.3% vs 57.7%,P=.065),且分娩孕周更晚、主要新生儿疾病发生率更低。
要点
- 17-α羟孕酮己酸酯起始孕周越早,分娩孕周越晚(P=.007)。
- 早期起始组复发性早产<37周发生率趋向低于晚期起始组(41.3% vs 57.7%,P=.065)。
- 早期起始组主要新生儿疾病发生率低于晚期起始组(1.5% vs 14.3%,P=.005)。
核心结论
- 既往16-28周自发性早产者复发性早产率较高。
- 较早起始17-α羟孕酮己酸酯者分娩孕周更晚且新生儿结局更好。
- 作者建议临床医生应尽一切努力促进在16周起始17-α羟孕酮己酸酯。
研究设计与样本
- 该研究为2005-2016年单家三级医疗中心的回顾性队列研究。
- 共纳入132例既往有16-28周自发性早产、本次单胎妊娠并接受17-α羟孕酮己酸酯的孕妇。
- 按17-α羟孕酮己酸酯起始孕周四分位分组:四分位1为14+0/7至16+1/7周,四分位2为16+2/7至17+0/7周,四分位3为17+1/7至18+6/7周,四分位4为19+0/7至27+5/7周。
- 四分位1和2为早期起始组,四分位3和4为晚期起始组。
主要发现
- 52例(39.6%)本次妊娠发生复发性早产<37周。
- 17-α羟孕酮己酸酯起始孕周平均为17+6/7±2.5周。
- 早期起始组复发性早产<37周发生率为41.3%,晚期起始组为57.7%(P=.065)。
- 分娩孕周随17-α羟孕酮己酸酯起始孕周四分位递增而递减:四分位1为37+4/7周,四分位2为36+5/7周,四分位3为36+1/7周,四分位4为34+0/7周(P=.007)。
- 早期起始组主要新生儿疾病发生率为1.5%,晚期起始组为14.3%(P=.005)。
临床怎么用
- 作者建议临床医生应尽一切努力促进在16周起始17-α羟孕酮己酸酯。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm birth is the leading cause of neonatal morbidity and mortality in nonanomalous neonates in the United States. Women with a previous early spontaneous preterm birth are at highest risk for recurrence. Weekly intramuscular 17-alpha hydroxyprogesterone caproate reduces the risk of recurrent prematurity. Although current guidelines recommend 17-alpha hydroxyprogesterone caproate initiation between 16 and 20 weeks, in clinical practice, 17-alpha hydroxyprogesterone caproate is started across a spectrum of gestational ages. OBJECTIVE: The objective of the study was to examine the relationship between the gestational age at 17-alpha hydroxyprogesterone caproate initiation and recurrent preterm birth among women with a prior spontaneous preterm birth 16-28 weeks' gestation. STUDY DESIGN: This was a retrospective cohort study of women from a single tertiary care center, 2005-2016. All women with ≥1 singleton preterm births because of a spontaneous onset of contractions, preterm prelabor rupture of membranes, or painless cervical dilation between 16 and 28 weeks followed by a subsequent singleton pregnancy treated with 17-alpha hydroxyprogesterone caproate were included. Women were grouped based on quartiles of gestational age of 17-alpha hydroxyprogesterone caproate initiation (quartile 1, 140/7 to 161/7; quartile 2, 162/7 to 170/7; quartile 3, 171/7 to 186/7; and quartile 4, 190/7 to 275/7). Women with a gestational age of 17-alpha hydroxyprogesterone caproate initiation in quartiles 1 and 2 were considered to have early-start 17-alpha hydroxyprogesterone caproate; those in quartiles 3 and 4 were considered to have late-start 17-alpha hydroxyprogesterone caproate. The primary outcome was recurrent preterm birth <37 weeks' gestation. Secondary outcomes included recurrent preterm birth <34 and <28 weeks' gestation and composite major neonatal morbidity (diagnosis of grade III or IV intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, necrotizing enterocolitis stage II or III, or death). Gestational age at delivery was compared by quartile of 17-alpha hydroxyprogesterone caproate initiation using Kaplan-Meier survival curves and the log-rank test. Logistic regression models estimated odds ratios for the association between gestational age at 17-alpha hydroxyprogesterone caproate initiation and preterm birth <37 weeks' gestation, adjusting for demographics, prior pregnancy and antenatal characteristics. RESULTS: A total of 132 women met inclusion criteria; 52 (39.6%) experienced recurrent preterm birth <37 weeks in the studied pregnancy. 17-Alpha hydroxyprogesterone caproate was initiated at a mean 176/7 ± 2.5 weeks. Demographic and baseline characteristics were similar between women with early-start 17-alpha hydroxyprogesterone caproate (quartiles 1 and 2) compared with those with late-start 17-alpha hydroxyprogesterone caproate (quartiles 3 and 4). Women with early-start 17-alpha hydroxyprogesterone caproate trended toward lower rates of recurrent preterm birth <37 weeks compared with those with late-start 17-alpha hydroxyprogesterone caproate (41.3% vs 57.7%, P = .065). Delivery gestational age was inversely proportional to gestational age at 17-alpha hydroxyprogesterone caproate initiation (quartile 1, 374/7 weeks vs quartile 2, 365/7 vs quartile 3, 361/7 weeks vs quartile 4, 340/7, P = .007). In Kaplan-Meier survival analyses, these differences in delivery gestational age by 17-alpha hydroxyprogesterone caproate initiation quartile persisted across pregnancy (log-rank P < .001). In regression models, later initiation of 17-alpha hydroxyprogesterone caproate was significantly associated with increased odds of preterm birth <37 weeks. Women with early 17-alpha hydroxyprogesterone caproate initiation also had lower rates of major neonatal morbidity than those with later 17-alpha hydroxyprogesterone caproate initiation (1.5% vs 14.3%, P = .005). CONCLUSION: Rates of recurrent preterm birth among women with a prior spontaneous preterm birth 16-28 weeks are high. Women beginning 17-alpha hydroxyprogesterone caproate early deliver later and have improved neonatal outcomes. Clinicians should make every effort to facilitate 17-alpha hydroxyprogesterone caproate initiation at 16 weeks.
引用
- Ning A, Vladutiu CJ, Dotters-Katz SK, et al. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth. Am J Obstet Gynecol. 2017. PMID: 28526452. doi:10.1016/j.ajog.2017.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。